



VG LIFE SCIENCES, INC. ANNOUNCES SEC FORM 10 REVIEW COMPLETE

SOURCE: VG Life Sciences, Inc.

SANTA BARBARA, Calif., October 14, 2014 (GLOBE NEWSWIRE) — VG Life Sciences Inc. (VGLS) is a publically traded biotechnology company focused on developing treatments for patients suffering from autoimmune and infectious diseases. VG Life Sciences is pleased to announce the Securities & Exchange Commission has completed their review of the company's Form 10 filing. The Form 10 was submitted on June 20, 2014 and provided comprehensive information about the capital structure, financial condition, history and governance of the company. A copy of the SEC letter is *here*.

The company is a reporting company and will file annual reports on form 10K, quarterly reports on 10Q and periodic reports on form 8K providing transparency with the investment community.

"This is yet another important commitment we made to our shareholders achieved in 2014," said John Tynan, President and CEO.

The company plans to move off the OTC Pink Marketplace and up to the OTCQB Marketplace.

About VG Life Sciences Inc.

Santa Barbara, California-based VG Life Sciences, Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious disease, and inflammatory, autoimmune disorders. VGLS controls over 45 US and international patents and pending patents protecting its exclusive biotech platform technologies. For more information and upcoming events, visit www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.

Safe Harbor Statement and Forward-Looking Statements

This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences Inc. or any other person that the objectives and plans of VG Life Sciences will be achieved.

Contact:

Allie Trabucco, Corporate Communications
VG Life Sciences, Inc.
Phone: (805) 879-9000
Email: atrabucco@vglifesciences.com

SOURCE VG Life Sciences Inc.